Navigation Links
Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
Date:5/29/2008

cessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, the Company's ability to obtain sufficient financing to

maintain the Company's planned operations, or the Company's risk of

bankruptcy if it is unsuccessful in obtaining such financing;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.

CONTACT:

Genta Investor Relations

info@genta.com


'/>"/>
SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... BERWYN, Pa. , July 25, 2014  AMETEK, ... appointment of Kurtis L. Goos as Vice ... Engineered Materials, Interconnects and Packaging (EMIP) Division. ... has extensive general management and business development experience, especially ... to make important contributions to the continued growth and ...
(Date:7/25/2014)... NORTH CHICAGO, Ill., July 25, 2014 ... PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION ... RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ... quarter ended June 30, 2014. "This was ... and earnings per share above our original guidance and announced ...
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... confirmed the PDUFA date for Zalviso remains July 27, ... rumor circulated online stating the Food and Drug Administration ... there has been no notification to the company from ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35
... 5, 2011 meridianEMR, the market leader in EHR ... Somerville, New Jersey was the first meridianEMR customer to ... Centers for Medicare and Medicaid Services (CMS). On July ... $54,000 for three physicians via direct deposit. The group ...
... Biotech Ltd. (Nasdaq: SVA ), a leading ... of Jacob Chik Keung Ho, its Chief Financial Officer, for ... a new Chief Financial Officer to replace Mr. Ho, who ... 2011.  Ms. Nan Wang, Vice President of Sinovac, has been ...
Cached Medicine Technology:meridianEMR® Customers Start Receiving Meaningful Use Incentive Payments 2meridianEMR® Customers Start Receiving Meaningful Use Incentive Payments 3Sinovac Announces Management Changes 2Sinovac Announces Management Changes 3
(Date:7/25/2014)... Agoura Hills dentist , Dr. Amir Choroomi, is ... is one of the most powerful whitening treatments available today, ... light-assisted treatment uses a prescription-strength gel that can penetrate quickly ... up stains that are in both the enamel and the ... and tobacco stains. , About Dr. Amir Choroomi, Expert ...
(Date:7/25/2014)... Health Advocate™, Inc., the nation’s leading ... West Corporation, is introducing its newest solution in an ... Enhance Quality. , The webinar will be held twice ... again at 2 PM ET. For more information or ... or call 866.799.2655. , In an environment of ...
(Date:7/25/2014)... quickly after Manchester research , Clinical judgement, combined ... arrival, is effective in reducing unnecessary hospital admissions ... findings of a research group in Manchester, published ... a huge difference to a large number of ... for emergency hospital admission. In Manchester, the incidence ...
(Date:7/25/2014)... prevents obesity could be on the horizon. Bacteria ... inhibit weight gain, insulin resistance and other adverse ... University investigators have discovered. , "Of course it,s ... senior investigator Sean Davies, Ph.D., assistant professor of ... negative consequences of obesity in mice, even though ...
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... JDRF’s revenue and spending during fiscal year 2013 (July 1, ... National Institutes of Health (NIH), the JDRF is the largest ... It has global reach and relationships with most of ... positioned to deliver a cure for type 1 diabetes in ...
Breaking Medicine News(10 mins):Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:Vanderbilt study examines bacteria's ability to fight obesity 2Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2
... to GSVM medical college in Kanpur remained affected today ... elite educational institutions entered the 11th day here. // ... the protest against Centre's decision to implement 27 per ... representatives of agitating doctors said., ,However, sources at ...
... a good way of relieving stress and providing the mind ... that exercise can lift a person's spirits// , and there ... clinical depression. Exercise helps in the reduction of anger, fatigue ... walking or running has become popular among health freaks. It ...
... some researchers found that milk chocolate containing caffeine has ... having better reaction times. ,Hence, chocolate ... others. ,Adding value to the above study, ... Professer, Dr. Bryan Raudenbush, Wheeling Jesuit University has done ...
... regulate breathing abnormalities of premature babies. Artificial breathing equipments ... with caffeine therapy and found to have a lower incidence ... , ,About 2,000 premature babies, who weighed below 1,250 grams, ... were studied. , ,More than 47 per ...
... direct talks with Prime Minister Manmohan Singh and decided to ... meeting with the medicos during which he told them that ... which would see a huge growth in the educational opportunities ... Prime Minister assured the medicos that they need not be ...
... A research conducted by the King’s Collage London, analysed health reports ... war in 2003 with those who took part// in the 1991 ... ,The study findings that are published in The Lancet ... War Syndrome" in British male armed forces personnel deployed to the ...
Cached Medicine News:
... non-adhesive sealing method maintains the ... (HALS) procedures, allowing the surgeon ... throughout. Because HALS requires incisions ... patients experience less trauma compared ...
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
... The SleepStyle 200 series offers ... integrated CPAP models. The design delivers ... patients. Performance features promote results in ... care. The strongest differentiator in the ...
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
Medicine Products: